由于股票价格低落,阿里戈斯治疗学在8月19日进行1-25次逆向股票分割。 Aligos Therapeutics to undergo 1-25 reverse stock split on Aug 19th due to low stock prices.

由于库存价格低,临床阶段生物制药公司Aligos治疗学将于8月19日进行逆向股票分割1至25。 Clinical-stage biopharmaceutical company Aligos Therapeutics is set to undergo a reverse stock split of 1-25 on August 19th due to low stock prices. 该公司专注于治疗病毒和肝脏疾病的新疗法,报告Q2每股收益为0.03美元,并正在进行非酒精性脂肪肝炎 (NASH) 的第二阶段临床试验,该试验的药物候选者是ALG-055009. The company, which focuses on novel therapeutics for viral and liver diseases, reported Q2 earnings of $0.03 per share and is in the process of a Phase 2a clinical trial for non-alcoholic steatohepatitis (NASH) with drug candidate ALG-055009. Acadian Asset Management LLC、Opaleye Management Inc.、Armistice Capital LLC 和 Altitude Crest Partners Inc. 等机构投资者增加了在该公司的股份。 Institutional investors like Acadian Asset Management LLC, Opaleye Management Inc., Armistice Capital LLC, and Altitude Crest Partners Inc. have increased their stakes in the company.